Jaroslav Jelinek

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia
    Jaroslav Jelinek
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e22110. 2011
  2. ncbi JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia
    Jaroslav Jelinek
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Blood 106:3370-3. 2005
  3. ncbi Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling
    Woonbok Chung
    Department of Leukemia, Baylor College of Medicine, Houston, Texas, United States of America
    PLoS ONE 3:e2079. 2008
  4. ncbi DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis
    Kazuo Konishi
    Department of Leukemia, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e27889. 2011
  5. ncbi Mechanisms of resistance to decitabine in the myelodysplastic syndrome
    Taichun Qin
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e23372. 2011
  6. ncbi Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation
    Jiali Si
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, TX, USA
    Cancer Res 70:6968-77. 2010
  7. ncbi Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes
    Yoshiyuki Watanabe
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Gastroenterology 136:2149-58. 2009
  8. ncbi Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse
    Heike Kroeger
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:1366-73. 2008
  9. ncbi DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory
    Noel J M Raynal
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Res 72:1170-81. 2012
  10. ncbi CpG island methylation profiling in human melanoma cell lines
    Carmen S Tellez
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Melanoma Res 19:146-55. 2009

Detail Information

Publications41

  1. ncbi Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia
    Jaroslav Jelinek
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e22110. 2011
    ..Finally, DNA methylation of PDLIM4 may help identify a subset of CML patients that would benefit from treatment with Src/Abl inhibitors...
  2. ncbi JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia
    Jaroslav Jelinek
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Blood 106:3370-3. 2005
    ..We conclude that the JAK2 1849G>T mutation is common in Ph(-) MPD but not critical for transformation to the acute phase of these diseases and that it is generally rare in aggressive leukemias...
  3. ncbi Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling
    Woonbok Chung
    Department of Leukemia, Baylor College of Medicine, Houston, Texas, United States of America
    PLoS ONE 3:e2079. 2008
    ..Our data identify new targets of transcriptional silencing in cancer, and provide new biomarkers that could be useful in screening for prostate cancer and other cancers...
  4. ncbi DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis
    Kazuo Konishi
    Department of Leukemia, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e27889. 2011
    ..The contribution of DNA methylation to the metastatic process in colorectal cancers (CRCs) is unclear...
  5. ncbi Mechanisms of resistance to decitabine in the myelodysplastic syndrome
    Taichun Qin
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e23372. 2011
    ..Therefore, we investigated mechanisms of primary and secondary resistance to DAC in MDS...
  6. ncbi Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation
    Jiali Si
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, TX, USA
    Cancer Res 70:6968-77. 2010
    ..Our findings suggest that gene expression is the key in optimizing DAC treatment strategies in the clinic...
  7. ncbi Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes
    Yoshiyuki Watanabe
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Gastroenterology 136:2149-58. 2009
    ..We hypothesized that methylation analysis of DNA recovered from gastric washes could be used to detect gastric cancer...
  8. ncbi Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse
    Heike Kroeger
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:1366-73. 2008
    ..0% to 15.2% (median 10.6%) genes in relapse (P < .001). Our data suggest that DNA methylation is involved in AML progression and provide a rationale for the use of epigenetic agents in remission maintenance...
  9. ncbi DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory
    Noel J M Raynal
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Res 72:1170-81. 2012
    ..These findings define chromatin as an important druggable target for cancer epigenetic therapy and suggest that removal of DNA methylation signals is required to achieve long-term gene reactivation...
  10. ncbi CpG island methylation profiling in human melanoma cell lines
    Carmen S Tellez
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Melanoma Res 19:146-55. 2009
    ..We conclude that aberrant hypermethylation, is frequent in melanoma cell lines, directly correlated with global DNA methylation, and independent of BRAF and NRAS mutations...
  11. ncbi Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
    Taichun Qin
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, USA
    Blood 113:659-67. 2009
    ..DAC induced DNA breaks as evidenced by H2AX phosphorylation and increased homologous recombination rates by 7- to 10-fold. These results suggest that in vitro resistance to DAC can be explained by insufficient incorporation into DNA...
  12. ncbi Epigenetic control of PRV-1 expression on neutrophils
    Jaroslav Jelinek
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Exp Hematol 35:1677-83. 2007
    ..We investigated whether DNA methylation of the PRV-1 gene has a role in regulation of transcription and expression of the PRV-1 protein...
  13. ncbi Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas
    David J Stewart
    M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 15:3881-8. 2009
    ..By hypomethylating genes, decitabine may up-regulate factors required for chemotherapeutic cytotoxicity. Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1...
  14. ncbi Effect of cytarabine and decitabine in combination in human leukemic cell lines
    Taichun Qin
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:4225-32. 2007
    ..5-Aza-2'-deoxycytidine (DAC) is a cytosine analogue that inhibits DNA methylation and also has activity in myeloid leukemia. Therefore, we investigated combining these two drugs in human leukemia cell lines in vitro...
  15. ncbi Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia
    Yasuhiro Oki
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:2382-4. 2008
    ..Our data suggest a predominantly noncytotoxic mechanism of action for decitabine, leading to altered biology of the neoplastic clone and/or normal cells. This trial was registered at www.ClinicalTrials.gov as #NCT00067808...
  16. ncbi LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability
    Marcos R H Estecio
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 2:e399. 2007
    ..This study was performed to determine the relationship between DNA hypomethylation, hypermethylation and microsatellite instability in cancer...
  17. ncbi Polycythemia vera is not initiated by JAK2V617F mutation
    Roberto H Nussenzveig
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Exp Hematol 35:32-8. 2007
    ..The somatic JAK2(V617F) mutation is seen in most polycythemia vera (PV) patients; however, it is not clear if JAK2(V617F) is the PV-initiating mutation...
  18. ncbi DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes
    Lanlan Shen
    Department of Leukemia and Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:605-13. 2010
    ..Epigenetic therapy using decitabine, a DNA hypomethylating agent, is clinically effective for the treatment of MDS. Therefore, we investigated the association between DNA methylation and clinical outcome in MDS...
  19. ncbi Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer
    Marcos R H Estecio
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Genome Res 20:1369-82. 2010
    ....
  20. ncbi Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer
    Yoshiyuki Watanabe
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e23320. 2011
    ..Mutations in MLL3 were found in a whole genome analysis of colorectal cancer but have not been confirmed by a separate study...
  21. ncbi Correlation between CpG methylation profiles and hormone receptor status in breast cancers
    Weiwei Feng
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Breast Cancer Res 9:R57. 2007
    ..The present study was undertaken to determine whether methylation of a set of growth-suppressor genes would correlate to the expression of estrogen receptors (ERs) and progesterone receptors (PRs)...
  22. ncbi Age-related DNA methylation changes in normal human prostate tissues
    Bernard Kwabi-Addo
    Department of Pathology, Baylor College of Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:3796-802. 2007
    ..We examined the extent of gene methylation in pathologically normal human prostate as a function of age...
  23. ncbi Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate
    Jean Pierre J Issa
    Department of Leukemia and Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:3948-56. 2005
    ..To determine the activity of decitabine, a DNA methylation inhibitor, in imatinib-refractory or intolerant chronic myelogenous leukemia...
  24. ncbi Analysis of epigenetic modifications by next generation sequencing
    Shoudan Liang
    Department of Bioinformatics and Computational Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Conf Proc IEEE Eng Med Biol Soc 2009:6730. 2009
    ..Several techniques useful in epigenetic data analysis will be discussed, mapping tags to reference genome incorporating all known SNPs, analysis of chIP-seq data, as well as restriction enzyme-based DNA methylation analysis...
  25. ncbi Delta DNMT3B variants regulate DNA methylation in a promoter-specific manner
    Jie Wang
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 67:10647-52. 2007
    ..We conclude that promoter DNA methylation can be differentially regulated and DeltaDNMT3Bs are involved in regulation of such promoter-specific de novo DNA methylation...
  26. ncbi Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia
    Jumpei Yamazaki
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Epigenetics 7:201-7. 2012
    ..0% and 9.8%, respectively) (p = 0.016). Thus, TET2 mutations affect global methylation in CMML but most of the changes are likely to be outside gene promoters...
  27. ncbi Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments
    Woonbok Chung
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 20:1483-91. 2011
    ..Bladder cancer (BCa) remains a lethal malignancy that can be cured if detected early. DNA hypermethylation is a common epigenetic abnormality in cancer that may serve as a marker of disease activity...
  28. ncbi Concordant DNA methylation in synchronous colorectal carcinomas
    Kazuo Konishi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 2:814-22. 2009
    ..Screening for and secondary prevention of colon cancer should take this fact into account...
  29. ncbi Search for genetic determinants of individual variability of the erythropoietin response to high altitude
    Katerina Jedlickova
    Baylor College of Medicine, Texas Medical Center, Houston, TX, USA
    Blood Cells Mol Dis 31:175-82. 2003
    ..In conclusion, we could find not convincing association between markers tightly linked to EPO or eight genes involved in Epo regulation and Epo differential responses to hypoxia...
  30. ncbi Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence
    Jei Kim
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biochim Biophys Acta 1772:72-80. 2007
    ..We suggest that focal epigenetic changes in estrogen receptor beta contribute to the development of atherosclerosis and vascular aging...
  31. ncbi Silencing of bidirectional promoters by DNA methylation in tumorigenesis
    Jingmin Shu
    Department of Leukemia, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 66:5077-84. 2006
    ....
  32. ncbi Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System
    Miloslav Beran
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Leuk Lymphoma 48:1150-60. 2007
    ....
  33. ncbi Disruption of ferroportin 1 regulation causes dynamic alterations in iron homeostasis and erythropoiesis in polycythaemia mice
    Henry Mok
    Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
    Development 131:1859-68. 2004
    ..Thus, our data suggest that a Hamp-mediated regulatory interference alleviates the defects in iron homeostasis and transient alterations in erythropoiesis caused by a regulatory mutation in Fpn1...
  34. ncbi Oxygen-dependent regulation of erythropoiesis
    Jaroslav Jelinek
    Department of Medicine, Hematology, and Oncology, Baylor College of Medicine, Houston, Texas 77030, USA
    Methods Enzymol 381:201-10. 2004
  35. ncbi Dnmt3a is essential for hematopoietic stem cell differentiation
    Grant A Challen
    Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, Texas, USA
    Nat Genet 44:23-31. 2012
    ..These data establish Dnmt3a as a critical participant in the epigenetic silencing of HSC regulatory genes, thereby enabling efficient differentiation...
  36. ncbi Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin
    Enli Liu
    Department of Hematology/Oncology, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 101:3294-301. 2003
    ..Thus, these novel clonality assays are useful in the diagnosis and follow-up of polycythemic conditions and disorders with increased platelet levels...
  37. ncbi Mutations and promoter methylation status of NPM1 in myeloproliferative disorders
    Yasuhiro Oki
    Haematologica 91:1147-8. 2006
    ..The mutations were present in 4% of chronic myelomonocytic leukemia, but not in other MPD or myelodysplastic syndromes. Promoter methylation was rare, and was found in only three samples of MPD...
  38. ncbi Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma
    Jared A Gollob
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Clin Cancer Res 12:4619-27. 2006
    ..To determine how a hypomethylating agent would modulate the toxicity and antitumor activity of immunotherapy, we initiated a phase I trial of 5-aza-2'-deoxycytidine (decitabine) plus high-dose interleukin 2 (IL-2)...
  39. ncbi Instability of PRV-1 mRNA: a factor to be considered in PRV-1 quantification for the diagnosis of polycythemia vera
    Jaroslav Jelinek
    Haematologica 89:749-51. 2004
    ..The instability of PRV-1 mRNA may affect the diagnostic value of the PRV-1 test in blood samples stored for extended periods...
  40. ncbi Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation
    Ting Xi Liu
    Laboratory of Development and Diseases, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    Nat Med 13:78-83. 2007
    ..Thus, loss of expression of the alpha-catenin tumor suppressor in hematopoietic stem cells may provide a growth advantage that contributes to human MDS or AML with del(5q)...
  41. ncbi RPS19 and JAK2 genes are not silenced by DNA methylation in diamond blackfan anemia
    Jaroslav Jelinek
    J Pediatr Hematol Oncol 29:207-8. 2007